Concizumab皮下预防治疗血友病A及伴抑制物血友病A/B的2期试验结果
两项concizumab 2期试验(explorer4纳入伴抑制物血友病A/B,explorer5纳入血友病A)评估每日皮下预防治疗,主要终点为最后剂量水平的年化出血率(ABR)。伴抑制物患者ABR低于血友病A患者,药代/药效符合预期,安全耐受良好,支持进一步开发。
要点
- 伴抑制物血友病A/B患者ABR分别为3.0和5.9,低于血友病A的7.0。
- 大多数抑制物患者(15/17,88.2%)未进行剂量递增。
- 无严重不良事件、无因不良事件退出、无血栓栓塞事件。
核心结论
- 两项试验均证实concizumab预防出血发作的临床概念验证,支持其作为所有血友病患者的每日预防治疗进一步开发。
研究设计与样本
- 两项concizumab 2期试验的主要部分(24周):explorer4纳入伴抑制物的血友病A或B(HAwI/HBwI),explorer5纳入血友病A(HA)。
- 患者接受0.15 mg/kg concizumab,若12周内≥3次自发性出血可递增至0.20和0.25 mg/kg。
主要发现
- HAwI和HBwI的估计ABR分别为3.0(95%CI 1.7;5.3)和5.9(95%CI 4.2;8.5),均低于HA的7.0(95%CI 4.6;10.7)。
- PK/PD结果符合预期,血友病亚型间concizumab暴露、游离组织因子途径抑制物、凝血酶生成、凝血酶原片段1+2和d-二聚体无差异。
- Concizumab安全且耐受良好,无严重不良事件、无不良事件相关退出、无血栓栓塞事件。
- 每项试验各有3例患者抗药抗体(ADA)检测阳性(极低至中等滴度),未观察到临床效应。
关键数值与推荐
- 主要终点为最后剂量水平的年化出血率(ABR)。
- 次要目标为安全性和免疫原性,分别以不良事件(AE)数量和抗药抗体(ADA)评估。
临床怎么用
- 每日皮下concizumab预防治疗在伴抑制物血友病A/B及血友病A中显示可预防出血发作。
- 大多数抑制物患者(15/17,88.2%)未需剂量递增,所有患者选择继续进入扩展期。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Results from the main parts (24 weeks) of 2 concizumab phase 2 trials are presented: explorer4 in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI) and explorer5 in HA. The trials aimed to evaluate the efficacy of daily subcutaneous concizumab prophylaxis (evaluated as annualized bleeding rate [ABR] at last dose level), with secondary objectives being safety and immunogenicity (assessed as number of adverse events [AEs] and antidrug antibodies [ADAs]). Patients received 0.15 mg/kg concizumab, with potential dose escalation to 0.20 and 0.25 mg/kg (if ≥3 spontaneous bleeding episodes within 12 weeks of concizumab treatment). Relevant pharmacokinetic/pharmacodynamic (PK/PD) parameters were assessed. Thirty-six HA, 9 HAwI, and 8 HBwI patients were exposed to concizumab. Most inhibitor patients (15 of 17; 88.2%) did not escalate the dose; all patients chose to continue to the extension phase of the trials. Clinical proof of concept for prevention of bleeding episodes was demonstrated in both trials. Estimated ABRs in HAwI and HBwI were lower vs HA: 3.0 (95% confidence interval [CI], 1.7; 5.3) and 5.9 (95% CI, 4.2; 8.5) vs 7.0 (95% CI, 4.6; 10.7), respectively. PK/PD results were as expected, with no difference between hemophilia subtypes for concizumab exposure, free tissue factor pathway inhibitor, thrombin generation, prothrombin fragment 1+2, and d-dimers. Concizumab was safe and well tolerated (no severe AEs, AE-related withdrawals, or thromboembolic events). Three patients had (very low to medium titer) ADA+ tests in each trial, with no observed clinical effect. These results support further development of concizumab as a daily prophylactic treatment in all hemophilia patients. These trials were registered at www.clinicaltrials.gov as #NCT03196284 and #NCT03196297.
引用
- Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019. PMID: 31444162. doi:10.1182/blood.2019001542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。